1xbet 사기 Senju Pharmaceutical Co., Ltd.
1xbet 사기 Pharmaceutical Co., Ltd.

Senju Pharmaceutical Co., Ltd. announces the launch today of "AIBETA^®Combination Ophthalmic Solution" (brimonidine tartrate and timolol maleate) for glaucoma and ocular hypertension in Japan. Activities to provide information on the drug are to be implemented by both Senju Pharmaceutical Co., Ltd. (marketing authorization holder) and 1xbet 사기 Pharmaceutical Co., Ltd. (alliance partner).

The only evidence-based reliable treatment 1xbet 사기 glaucoma is to reduce the intraocular pressure. Usually, treatment is started with a single therapeutic agent. Then, if the effect is insufficient, combination therapy is per1xbet 사기med. In such a case, it is necessary to consider dose adherence of patients by using a combination ophthalmic solution.

Brimonidine tartrate is an intraocular pressure-lowering agent highly selective 1xbet 사기 adrenaline α₂receptor and has been marketed by Senju with a brand name "Aiphagan^®Ophthalmic Solution 0.1%" since May 2012. The new drug is the first combination ophthalmic solution containing brimonidine tartrate in Japan and expected to contribute to improving the adherence of many glaucoma patients who are concomitantly treated with brimonidine tartrate and timolol maleate with each separate single 1xbet 사기mulation.